L. Colangelo

发表

Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.

N. Petrelli, N. Wolmark, M. O’connell, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

N. Petrelli, N. Wolmark, R. Goldberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.

N. Petrelli, N. Wolmark, R. Goldberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.

Norman Wolmark, Patrick G Johnston, P. Johnston, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.

N. Petrelli, N. Wolmark, M. O’connell, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.

N. Petrelli, N. Wolmark, M. O’connell, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to R. Glynne-Jones et al

N. Wolmark, M. O’connell, M. Deutsch, 2010 .

Predictive Biomarkers and Personalized Medicine MutationPro fi ling andMicrosatellite Instability in Stage II and III Colon Cancer : An Assessment of Their Prognostic and Oxaliplatin Predictive Value

N. Petrelli, S. Paik, Chungyeul Kim, 2012 .

Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.

J. Kopec, D. Cella, J. Costantino, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.

N. Wolmark, Roy E. Smith, M. Begovic, 2004, Journal of the National Cancer Institute.

Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5‐fluorouracil/leucovorin plus or minus oxaliplatin

N. Wolmark, M. O’connell, Roy E. Smith, 2007, Cancer.

Durable improvement in disease-free survival (DFS) and overall survival (OS) for stage II or III colon cancer treated with leucovorin-modulated fluorouracil (FL): 10-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol C-03

N. Petrelli, N. Wolmark, M. O’connell, 2005 .

Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program.

C. Geyer, N. Wolmark, Roy E. Smith, 2005, Clinical colorectal cancer.

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

N. Petrelli, N. Wolmark, M. O’connell, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07

N. Wolmark, M. O’connell, S. Wieand, 2005 .

National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.

N. Wolmark, S. Wieand, L. Colangelo, 2001, Seminars in oncology.

Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project.

D. Wickerham, N. Wolmark, Roy E. Smith, 1999, Journal of the National Cancer Institute.

Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum.

N. Petrelli, N. Wolmark, M. O’connell, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive value of microsatellite instability-high remains controversial.

S. Paik, N. Wolmark, M. O’connell, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06.

N. Wolmark, R. Pazdur, S. Wieand, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

R. Hays, C. Ko, K. Spritzer, 2022, Cancer.

A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06

N. Wolmark, R. Pazdur, Roy E. Smith, 2004 .

Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.

Daniel J Sargent, Daniel G Haller, Joel E Tepper, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.

H. Rockette, N. Petrelli, D. Wickerham, 2000, Journal of the National Cancer Institute.

Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

Greg Yothers, Hyun Joo Choi, Debora Fumagalli, 2012, Clinical Cancer Research.

Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.

N. Petrelli, S. Paik, N. Wolmark, 2013, Journal of the National Cancer Institute.

Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.

Norman Wolmark, Soonmyung Paik, S. Paik, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.

N. Wolmark, M. O’connell, J. Dignam, 2006, Journal of the National Cancer Institute.

Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials.

N. Wolmark, Roy E. Smith, E. Mamounas, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.

N. Petrelli, R. Beart, N. Wolmark, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.

N. Wolmark, R. Valicenti, G. Yothers, 2021, JAMA oncology.

Genetic Variant Associated with Survival of Patients with Stage II-III Colon Cancer.

Stephanie A. Bien, A. Joshi, Wei Sun, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

H. Gómez, N. Robert, C. Geyer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32.

T. Julian, J. Kopec, N. Wolmark, 2012, The journal of supportive oncology.

Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC).

G. Yothers, T. George, L. Kachnic, 2023, Journal of Clinical Oncology.

Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.

J. Bryant, N. Wolmark, J. Grem, 1998, Journal of the National Cancer Institute.

UFT plus calcium folinate vs 5-FU plus calcium folinate in colon cancer.

D. Wickerham, H. Wieand, L. Colangelo, 1999, Oncology.

Assessing the Quality of Rectal Cancer Pathology Reports in National Surgical Adjuvant Breast and Bowel Project Protocol R-04/NRG Oncology

R. Beart, C. Ko, P. Ganz, 2020, Diseases of the colon and rectum.

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—Pembrolizumab experimental arm (EA) primary results.

N. Wolmark, G. Yothers, T. George, 2021 .

UFT/leucovorin vs 5-FU/leucovorin in colon cancer.

B. Lembersky, H. Wieand, L. Colangelo, 2000, Oncology.

Patient-reported neurotoxicity with FULV versus FLOX in patients with stage II or III carcinoma of the colon: Results of NSABP Protocol C-07.

J. Kopec, J. Costantino, N. Wolmark, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum

N. Petrelli, N. Wolmark, M. O’connell, 2004 .

Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia.

E. Vichinsky, C. Pegelow, E. Vichinsky, 1997, The American journal of medicine.

Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.

N. Petrelli, S. Paik, N. Wolmark, 2013, Journal of the National Cancer Institute.

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

N. Petrelli, N. Wolmark, R. Goldberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

N. Petrelli, S. Paik, Chungyeul Kim, 2012, Clinical Cancer Research.